Janet Peterson

737 total citations
18 papers, 545 citations indexed

About

Janet Peterson is a scholar working on Epidemiology, Pharmacology and Molecular Medicine. According to data from OpenAlex, Janet Peterson has authored 18 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 9 papers in Pharmacology and 4 papers in Molecular Medicine. Recurrent topics in Janet Peterson's work include Antibiotics Pharmacokinetics and Efficacy (8 papers), Pneumonia and Respiratory Infections (6 papers) and Urinary Tract Infections Management (4 papers). Janet Peterson is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (8 papers), Pneumonia and Respiratory Infections (6 papers) and Urinary Tract Infections Management (4 papers). Janet Peterson collaborates with scholars based in United States, Netherlands and Austria. Janet Peterson's co-authors include Alan C. Fisher, James B. Kahn, ‏Mohammed ‏Khashab, Simrati Kaul, Susan Nicholson, Behin Yektashenas, Juan F. Fernandez, Marcos I. Restrepo, Daniel F. Sahm and A. Simon Lynch and has published in prestigious journals such as Drugs, Urology and Clinical Therapeutics.

In The Last Decade

Janet Peterson

18 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janet Peterson United States 10 331 171 118 101 97 18 545
Joe Amoah United States 16 335 1.0× 180 1.1× 128 1.1× 40 0.4× 240 2.5× 25 712
Deborah Church United States 8 501 1.5× 142 0.8× 172 1.5× 224 2.2× 52 0.5× 8 661
Xavier Roux Switzerland 10 220 0.7× 53 0.3× 29 0.2× 39 0.4× 21 0.2× 21 484
Joseph Kohn United States 17 368 1.1× 241 1.4× 194 1.6× 50 0.5× 393 4.1× 50 859
Cynthia Fatica United States 11 185 0.6× 140 0.8× 52 0.4× 17 0.2× 76 0.8× 18 467
David X. Li United States 6 217 0.7× 46 0.3× 79 0.7× 34 0.3× 227 2.3× 9 598
Chris A. Gentry United States 15 327 1.0× 76 0.4× 141 1.2× 43 0.4× 104 1.1× 40 682
Christopher Jankowski United States 11 179 0.5× 74 0.4× 179 1.5× 20 0.2× 127 1.3× 23 540
Danielle Osterholzer United States 10 250 0.8× 17 0.1× 64 0.5× 83 0.8× 168 1.7× 25 479
Martin Štěpán Czechia 13 468 1.4× 49 0.3× 103 0.9× 46 0.5× 39 0.4× 24 873

Countries citing papers authored by Janet Peterson

Since Specialization
Citations

This map shows the geographic impact of Janet Peterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet Peterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet Peterson more than expected).

Fields of papers citing papers by Janet Peterson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet Peterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet Peterson. The network helps show where Janet Peterson may publish in the future.

Co-authorship network of co-authors of Janet Peterson

This figure shows the co-authorship network connecting the top 25 collaborators of Janet Peterson. A scholar is included among the top collaborators of Janet Peterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet Peterson. Janet Peterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Morrow, Brian J., Jennifer Deane, Daniel F. Sahm, et al.. (2013). Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. Diagnostic Microbiology and Infectious Disease. 75(4). 412–416. 40 indexed citations
2.
Restrepo, Marcos I., et al.. (2013). Comparison of the Bacterial Etiology of Early-Onset and Late-Onset Ventilator-Associated Pneumonia in Subjects Enrolled in 2 Large Clinical Studies. Respiratory Care. 58(7). 1220–1225. 85 indexed citations
3.
Queenan, Anne Marie, Chris M. Pillar, Jennifer Deane, et al.. (2012). Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagnostic Microbiology and Infectious Disease. 73(3). 267–270. 65 indexed citations
4.
Nicholson, Susan, Janet Peterson, & Behin Yektashenas. (2012). Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed. Expert Opinion on Drug Safety. 11(2). 299–314. 3 indexed citations
5.
Nicholson, Susan, Janet Peterson, & Behin Yektashenas. (2011). Risk Evaluation and Mitigation Strategies (REMS). Drug Safety. 35(2). 91–104. 45 indexed citations
6.
Peterson, Janet, et al.. (2010). Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis. Current Medical Research and Opinion. 26(6). 1433–1441. 8 indexed citations
7.
Peterson, Janet, Behin Yektashenas, & Alan C. Fisher. (2009). Levofloxacin for the treatment of pneumonia caused byStreptococcus pneumoniaeincluding multidrug-resistant strains: pooled analysis. Current Medical Research and Opinion. 25(3). 559–568. 2 indexed citations
8.
Nord, Carl Erik, et al.. (2009). Levofloxacin versus azithromycin on the oropharyngeal carriage and selection of antibacterial- resistant streptococci in the microflora of healthy adults. Current Medical Research and Opinion. 25(6). 1461–1467. 4 indexed citations
9.
Jenkins, Stephen G., Alan C. Fisher, Janet Peterson, Susan Nicholson, & Koné Kaniga. (2009). Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials. Current Medical Research and Opinion. 25(12). 3029–3036. 7 indexed citations
10.
11.
Raingruber, Bonnie, et al.. (2007). The Use of Knee-Length Versus Thigh-Length Compression Stockings and Sequential Compression Devices. Critical Care Nursing Quarterly. 30(3). 255–262. 20 indexed citations
12.
Peterson, Janet, Simrati Kaul, ‏Mohammed ‏Khashab, Alan C. Fisher, & James B. Kahn. (2007). Identification and Pretherapy Susceptibility of Pathogens in Patients with Complicated Urinary Tract Infection or Acute Pyelonephritis Enrolled in a Clinical Study in the United States from November 2004 Through April 2006. Clinical Therapeutics. 29(10). 2215–2221. 26 indexed citations
13.
Klausner, Howard, Patricia D. Brown, Janet Peterson, et al.. (2007). A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Current Medical Research and Opinion. 23(11). 2637–2645. 67 indexed citations
14.
Lin, Chin‐Chung, et al.. (2005). Pharmacokinetics of Pradefovir and PMEA in Healthy Volunteers After Oral Dosing of Pradefovir. The Journal of Clinical Pharmacology. 45(11). 1250–1258. 15 indexed citations
15.
Peterson, Janet. (2005). Understanding Fibromyalgia and Its Treatment Options. The Nurse Practitioner. 30(1). 48–55. 6 indexed citations
16.
Xu, Christine, Janet Peterson, Li‐Tain Yeh, et al.. (2005). Ascending Multiple‐Dose Pharmacokinetics of Viramidine, a Prodrug of Ribavirin, in Adult Subjects With Compensated Hepatitis C Infection. The Journal of Clinical Pharmacology. 45(3). 275–285. 12 indexed citations
17.
18.
Peterson, Janet. (1999). Oral Trovafloxacin vs Oral Cefuroxime ?? Erythromycin in Community-Acquired Pneumonia. Drugs. 58(Supplement 2). 301–303. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joe Amoah Breakdown of academic impact, for papers by Deborah Church Breakdown of academic impact, for papers by Xavier Roux Breakdown of academic impact, for papers by Joseph Kohn Breakdown of academic impact, for papers by Cynthia Fatica Breakdown of academic impact, for papers by David X. Li Breakdown of academic impact, for papers by Chris A. Gentry Breakdown of academic impact, for papers by Christopher Jankowski Breakdown of academic impact, for papers by Danielle Osterholzer Breakdown of academic impact, for papers by Martin Štěpán
Rankless by CCL
2026